Mesenchymal Stem Cell Therapy for Osteogenesis Imperfecta.
Clin Obstet Gynecol
; 64(4): 898-903, 2021 12 01.
Article
em En
| MEDLINE
| ID: mdl-34510048
ABSTRACT
The aim of this study was to provide a brief overview on the background and rationale on treating fetuses and children suffering from osteogenesis imperfecta (OI) with mesenchymal stem cells (MSCs). MSCs ability to migrate, engraft, and differentiate into bone cells and to act via paracrine effects on the recipient's tissues makes these cells promising candidates as a clinical therapy for OI. Animal work and limited clinical studies in humans support the use of MSC in treating OI. Off-the-shelf MSC have a good safety profile and exhibit multilineage differentiation potential and a low immunogenic profile and thereby may enable this potential therapy to become widely available. MSC transplantation before and after birth to treat OI is an experimental therapy that is currently tested in the international multicentre phase I/II clinical trial BOOSTB4 that aims to assess the safety and efficacy of fetal MSC transplantation for the treatment of severe types of OI.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Osteogênese Imperfeita
/
Transplante de Células-Tronco Mesenquimais
/
Células-Tronco Mesenquimais
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Clin Obstet Gynecol
Ano de publicação:
2021
Tipo de documento:
Article